NYSEAMERICAN:ISRIsoRay Stock Price, Forecast & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IsoRay in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IsoRay.

IsoRay is scheduled to release its next quarterly earnings announcement on Tuesday, September 22nd 2020. View our earnings forecast for IsoRay.

IsoRay, Inc. (NYSEAMERICAN:ISR) issued its earnings results on Tuesday, May, 12th. The healthcare company reported ($0.01) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.01). The healthcare company earned $2.88 million during the quarter, compared to analyst estimates of $2.76 million. View IsoRay's earnings history.

2 equities research analysts have issued twelve-month price targets for IsoRay's shares. Their forecasts range from $1.25 to $1.75. On average, they expect IsoRay's share price to reach $1.50 in the next year. This suggests a possible upside of 127.8% from the stock's current price. View analysts' price targets for IsoRay.

Headlines about ISR stock have been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. IsoRay earned a news sentiment score of -2.4 on InfoTrie's scale. They also gave headlines about the healthcare company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news about IsoRay.

IsoRay saw a decline in short interest in June. As of June 30th, there was short interest totaling 1,730,000 shares, a decline of 20.3% from the June 15th total of 2,170,000 shares. Based on an average daily trading volume, of 478,900 shares, the short-interest ratio is currently 3.6 days. Approximately 2.6% of the shares of the company are sold short. View IsoRay's Current Options Chain.

Some companies that are related to IsoRay include Retractable Technologies (RVP), CRH Medical (CRHM), CRH Medical (CRHM), SDI (SDI), Milestone Scientific (MLSS), Omega Diagnostics Group (ODX), Daxor (DXR), Daxor (DXR), TSO3 (TOS), Impression Healthcare (IHL), G Medical (GMV), TransEnterix (TRXC), Akers Biosciences (AKR), Relevium Technologies (RLV) and Vigil Health Solutions (VGL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other IsoRay investors own include Brainstorm Cell Therapeutics (BCLI), Opko Health (OPK), Bausch Health Companies (BHC), NovaBay Pharmaceuticals (NBY), MannKind (MNKD), TherapeuticsMD (TXMD), Anavex Life Sciences (AVXL), Plug Power (PLUG), Catalyst Pharmaceuticals (CPRX) and Inovio Pharmaceuticals (INO).

IsoRay trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."

Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ISR stock can currently be purchased for approximately $0.66.

IsoRay has a market capitalization of $44.55 million. IsoRay employs 38 workers across the globe.

The official website for IsoRay is isoray.com.

IsoRay's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The healthcare company can be reached via phone at +1-509-3751202.